Innate Pharma S.A.

Informe acción ENXTPA:IPH

Capitalización de mercado: €139.6m

Innate Pharma Dirección

Dirección controles de criterios 4/4

El CEO de Innate Pharma es Herve Brailly, nombrado en Jan 1999, tiene una permanencia de 25.75 años. posee directamente un 0.91% de las acciones de la empresa, con un valor de €1.28M. La antigüedad media del equipo directivo y de la junta directiva es de 4.6 años y 5.9 años, respectivamente.

Información clave

Herve Brailly

Chief Executive Officer (CEO)

€100.0k

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO25.8yrs
Participación del CEO0.9%
Permanencia media de la dirección4.6yrs
Promedio de permanencia en la Junta Directiva5.9yrs

Actualizaciones recientes de la dirección

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)

Oct 24
Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)

Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price

May 21
Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price

Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Mar 24
Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Dec 21
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher

Sep 30
Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher

Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates

Sep 16
Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Jun 09
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts

Mar 30
News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts

Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic

Dec 18
Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic

Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?

Sep 27
Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?

Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year

Aug 04
Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year

Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

May 12
Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Apr 13
Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Time To Worry? Analysts Just Downgraded Their Innate Pharma S.A. (EPA:IPH) Outlook

Mar 26
Time To Worry? Analysts Just Downgraded Their Innate Pharma S.A. (EPA:IPH) Outlook

Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?

Nov 11
Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?

CEO

Herve Brailly (63 yo)

25.8yrs

Permanencia

€100,000

Compensación

Dr. Herve Brailly, Ph.D. Co-Founded Innate Pharma S.A in 1999 and served as its Chairman of Supervisory Board since December 31, 2016 until January 1, 2024 and serves as its Interim CEO and Chairman of the...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Herve Brailly
Co-Founder25.8yrs€100.00k0.91%
€ 1.3m
Yannis Morel
Executive VP9.4yrs€599.92k0.24%
€ 334.8k
François Romagné
Founderno datasin datossin datos
Eric Vivier
Founder6.8yrssin datos0.26%
€ 362.4k
Marc Bonneville
Founderno datasin datossin datos
Jean Fournié
Founderno datasin datossin datos
Alessandro Moretta
Founderno datasin datossin datos
Frederic Lombard
Senior VP & CFO3.5yrssin datos0.014%
€ 19.6k
Sonia Quaratino
Executive VPless than a yearsin datossin datos
Arvind Sood
Executive VPless than a yearsin datossin datos
Henry Wheeler
Vice President of Investor Relations & Communication1.8yrssin datos0.0039%
€ 5.5k
Odile Belzunce
Vice President of Compliance & Operations5.8yrssin datos0.077%
€ 107.3k

4.6yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IPH se considera experimentado (4.6 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Mario Sznol
Strategic Advisory Board Member5.9yrssin datossin datos
Olivier Martinez
Member of Supervisory Boardno datasin datossin datos
Diane Mathis
Strategic Advisory Boardless than a yearsin datossin datos
Gilles Brisson
Independent Member of Supervisory Board17.3yrs€29.00k0.090%
€ 126.0k
Sally Bennett
Independent Supervisory Board Member2.4yrs€45.00k0.0031%
€ 4.3k
Jean-Yves Blay
Independent Member of Supervisory Board6.8yrs€29.00k0.000060%
€ 83.7
Irina Staatz-Granzer
Independent Chairwoman of Supervisory Board15.3yrs€42.00k0.031%
€ 43.3k
Pascale Boissel
Independent Vice Chairperson of the Supervisory Board4.4yrs€60.00k0.0012%
€ 1.7k
Miriam Merad
Chairman of Strategic Advisory Board5.9yrssin datossin datos
Veronique Chabernaud
Independent Member of Supervisory Board9.5yrs€48.00k0.00082%
€ 1.1k
Katy Rezvani
Strategic Advisory Boardless than a yearsin datossin datos
Aurelien Marabelle
Strategic Advisory Board Member5.9yrssin datossin datos

5.9yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de IPH se considera experimentada (5.9 años de antigüedad promedio).